News stories about Uroplasty (NYSE:UPI) have been trending positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Uroplasty earned a news impact score of 0.50 on Accern’s scale. Accern also gave headlines about the medical device company an impact score of 75 out of 100, meaning that recent news coverage is likely to have an impact on the company’s share price in the near term.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with our FREE daily email newsletter.